Figure 4.
Tumor-specific accumulation of PLT/CANS. A) Nanoparticle blood clearance in healthy mice. B) Nanoparticle biodistribution at 24 h postinjection in an orthotopic colon cancer model. C) Fluorescence images of major organs and tumors at 24 h postinjection. D) PA images of tumors before and after nanoparticle administration. E) Semiquantitative analysis of the fluorescence imaging signal in major organs and tumors at 24 h postinjection. F) Semiquantitative analysis of the PA signal in the tumor before and after nanoparticle administration. * P < 0.1; ** P < 0.01; *** P < 0.001.
